TherapeuticsMD Inc
TXMD1.110USD
0.000
Market hours （ET）Quotes delayed by 15 min
12.85MMarket Cap
LossP/E TTM
More Details of TherapeuticsMD Inc Company
TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).
Company Info
Ticker SymbolTXMD
Company nameTherapeuticsMD Inc
IPO dateJan 31, 2001
CEOMr. Marlan D. Walker, J.D.
Number of employees1
Security typeOrdinary Share
Fiscal year-endJan 31
Address951 Yamato Road, Suite 220
CityBOCA RATON
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code33431
Phone15619611900
Websitehttps://www.therapeuticsmd.com/
Ticker SymbolTXMD
IPO dateJan 31, 2001
CEOMr. Marlan D. Walker, J.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Marlan D. Walker, J.D.
Mr. Marlan D. Walker, J.D.
Chief Executive Officer
Chief Executive Officer
73.64K
+3.94%
Mr. Cooper C. Collins
Mr. Cooper C. Collins
Independent Director
Independent Director
60.52K
--
Dr. Gail K. Naughton, Ph.D.
Dr. Gail K. Naughton, Ph.D.
Independent Director
Independent Director
8.50K
--
Mr. Joseph Ziegler
Mr. Joseph Ziegler
Principal Financial Officer, Principal Accounting Officer
Principal Financial Officer, Principal Accounting Officer
7.50K
--
Mr. Justin Roberts
Mr. Justin Roberts
Independent Director
Independent Director
--
--
Gov. Thomas G. (Tommy) Thompson, J.D.
Gov. Thomas G. (Tommy) Thompson, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Marlan D. Walker, J.D.
Mr. Marlan D. Walker, J.D.
Chief Executive Officer
Chief Executive Officer
73.64K
+3.94%
Mr. Cooper C. Collins
Mr. Cooper C. Collins
Independent Director
Independent Director
60.52K
--
Dr. Gail K. Naughton, Ph.D.
Dr. Gail K. Naughton, Ph.D.
Independent Director
Independent Director
8.50K
--
Mr. Joseph Ziegler
Mr. Joseph Ziegler
Principal Financial Officer, Principal Accounting Officer
Principal Financial Officer, Principal Accounting Officer
7.50K
--
Mr. Justin Roberts
Mr. Justin Roberts
Independent Director
Independent Director
--
--
Gov. Thomas G. (Tommy) Thompson, J.D.
Gov. Thomas G. (Tommy) Thompson, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
No Data
By RegionUSD
Name
Revenue
Proportion
Non-U.S
219.00K
55.73%
United States
174.00K
44.27%
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Rubric Capital Management LP
25.46%
Clearline Capital LP
5.49%
The Vanguard Group, Inc.
3.30%
Tejara Capital Ltd.
2.98%
Adar1 Capital Management LLC
2.33%
Other
60.44%
Shareholders
Shareholders
Proportion
Rubric Capital Management LP
25.46%
Clearline Capital LP
5.49%
The Vanguard Group, Inc.
3.30%
Tejara Capital Ltd.
2.98%
Adar1 Capital Management LLC
2.33%
Other
60.44%
Shareholder Types
Shareholders
Proportion
Hedge Fund
33.68%
Investment Advisor
7.67%
Investment Advisor/Hedge Fund
1.60%
Individual Investor
1.55%
Research Firm
1.14%
Other
54.36%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
88
5.28M
45.65%
+1.46M
2025Q1
93
3.58M
30.94%
-393.28K
2024Q4
95
3.73M
32.32%
-2.03M
2024Q3
99
3.59M
31.15%
-463.34K
2024Q2
121
3.62M
31.37%
-2.25M
2024Q1
209
3.66M
32.13%
-802.21K
2023Q4
230
4.54M
44.12%
-1.60M
2023Q3
274
4.44M
43.31%
-158.22K
2023Q2
299
4.48M
44.55%
-545.84K
2023Q1
319
4.85M
52.06%
-356.05K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Rubric Capital Management LP
2.95M
25.46%
+1.75M
+147.18%
Apr 18, 2025
Clearline Capital LP
635.22K
5.49%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
381.94K
3.3%
-5.64K
-1.46%
Mar 31, 2025
Tejara Capital Ltd.
344.60K
2.98%
-50.07K
-12.69%
Mar 31, 2025
Adar1 Capital Management LLC
270.16K
2.33%
--
--
Mar 31, 2025
Morgan Stanley & Co. LLC
130.12K
1.12%
-314.00
-0.24%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
116.13K
1%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
111.51K
0.96%
+3.17K
+2.93%
Mar 31, 2025
Walker (Marlan D)
73.64K
0.64%
+2.79K
+3.94%
Apr 18, 2025
Collins (Cooper C)
60.52K
0.52%
--
--
Apr 18, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
May 06, 2022
Merger
50<1
May 06, 2022
Merger
50<1
May 06, 2022
Merger
50<1
May 06, 2022
Merger
50<1
Date
Type
Ratio
May 06, 2022
Merger
50<1
May 06, 2022
Merger
50<1
May 06, 2022
Merger
50<1
May 06, 2022
Merger
50<1
